Adjunctive huperzine A for cognitive deficits in schizophrenia: a systematic review and meta-analysis

Abstract

This review suggests that adjunctive HupA is an effective choice for improving cognitive function for patients with schizophrenia spectrum disorders. More well-designed RCTs are needed to further confirm HupA's efficacy. Copyright © 2016 John Wiley & Sons, Ltd.

Erythropoietin for Cognitive Deficits Associated with Schizophrenia, Bipolar Disorder, and Major Depression: A Systematic Review

“…As a hematopoietic growth factor, EPO has a direct effect on cells in the nervous system, which may result in improvement on cognitive deficits [24]. Other mechanisms of EPO's effect on cognitive deficits include the activation of antiapoptotic, antioxidant, and anti-inflammatory signaling in neurons, glial, and cerebrovascular endothelial cells; the promotion of dendritic sprouting; and upregulation of hippocampal brain-derived neurotrophic factor and neurogenesis [24][25][26].…”

“…A meta-analysis found that adjunctive memantine (20 mg/d) was superior to placebo in improving neurocognitive performance in schizophrenia [29]. Other adjunctive medications, such as HupA [25,30], also showed beneficial effects on neurocognitive functions for patients with schizophrenia or major depression. In the current study, EPO appeared to be effective for treating cognitive deficits in schizophrenia and bipolar and depressive disorders with no major adverse effects.…”

Enantioselective Total Synthesis of (+)-Sieboldine A

“… (+)-Sieboldine A ( 1 ) has been found to inhibit acetylcholinesterase (from the electric eel) with an IC 50 value of 2.0 μM. This value was comparable to that of (±)-huperzine A and exhibited cytotoxicity against murine lymphoma L1210 cells with an IC 50 value of 5.1 μg/mL …”